UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 2, 2006

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, or a non-accelerated filer. See

definition of "accelerated filer and large accelerated filer" in

Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer X

Accelerated Filer Non-accelerated

filer

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At May 2, 2006, 7,327,389,419 shares of the

issuer's voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

April 2, 2006

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements:

Condensed

Consolidated Statements of Income for the three months ended April 2,

2006 and April 3, 2005

Condensed

Consolidated Balance Sheets at April 2, 2006 and

December 31, 2005

Condensed

Consolidated Statements of Cash Flows for the three months ended

April 2, 2006 and April 3, 2005

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

20

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

21

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

46

Item 4.

Controls and

Procedures

46

PART II. OTHER

INFORMATION

Item 1.

Legal Proceedings

47

Item 1A.

Risk Factors

48

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

48

Item 3.

Defaults Upon

Senior Securities

48

Item 4.

Submission of

Matters to a Vote of Security Holders

48

Item 5

Other

Information

50

Item 6.

Exhibits

50

Signature

51

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(millions

of dollars, except per common share data)

April 2,

2006

April 3,

2005

Revenues

12,660

13,091

Costs

and expenses:

Cost of sales(a)

1,973

2,191

Selling, informational and administrative expenses(a)

3,810

4,085

Research and development expenses(a)

1,588

1,764

Amortization of intangible assets

828

882

Merger-related in-process research and development

charges

--

Restructuring charges and merger-related costs

306

219

Other (income)/deductions - net

(272)

1,038

Income from continuing operations before provision

for taxes on income and minority interests

4,427

2,910

Provision for taxes on income

315

2,635

Minority interests

Income from continuing operations

4,108

272

Discontinued operations:

Loss from discontinued operations - net of tax

--

(12)

Gains on sales of discontinued operations - net of

tax

41

Discontinued operations - net of tax

29

Net income

4,111

301

Earnings

per common share - basic:

Income from continuing operations

0.56

0.04

Discontinued operations - net of tax

--

--

Net income

0.56

0.04

Earnings

per common share - diluted:

Income from continuing operations

0.56

0.04

Discontinued operations - net of tax

--

--

Net income

0.56

0.04

Weighted-average shares used to calculate earnings

per common share:

Basic

7,314

7,416

Diluted

7,324

7,474

Cash

dividends paid per common share

0.24

0.19

(a)

Exclusive

of amortization of intangible assets, except as disclosed in Note 11B, Goodwill

and Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

April 2,

2006*

Dec. 31,

2005**

ASSETS

Current Assets

Cash and cash

equivalents

2,869

2,247

Short-term

investments

12,633

19,979

Accounts

receivable, less allowance for doubtful accounts

10,352

9,765

Short-term

loans

445

510

Inventories

6,663

6,039

Prepaid

expenses and taxes

4,302

3,196

Assets held for

sale

151

160

Total current assets

37,415

41,896

Long-term

investments and loans

2,543

2,497

Property, plant and equipment, less

accumulated depreciation

17,103

17,090

Goodwill

23,741

23,774

Identifiable

intangible assets, less accumulated amortization

28,073

27,786

Other assets,

deferred taxes and deferred charges

4,084

4,522

Total assets

112,959

117,565

LIABILITIES

AND SHAREHOLDERS' EQUITY

Current Liabilities

Short-term

borrowings, including current portion of long-term debt

5,059

11,589

Accounts

payable

1,892

2,226

Dividends

payable

1,772

Income taxes

payable

3,495

3,617

Accrued

compensation and related items

1,504

1,675

Other current

liabilities

7,717

7,522

Liabilities held

for sale

Total current liabilities

19,674

28,403

Long-term debt

6,508

6,347

Pension benefit

obligations

2,665

2,717

Postretirement

benefit obligations

1,448

1,443

Deferred taxes

10,337

10,240

Other

noncurrent liabilities

2,718

2,651

Total liabilities

43,350

51,801

Shareholders' Equity

Preferred stock

159

169

Common stock

439

439

Additional

paid-in capital

67,931

67,759

Employee

benefit trust, at fair value

(729)

(923)

Treasury stock

(40,757)

(39,767)

Retained

earnings

41,715

37,608

Accumulated

other comprehensive income

851

479

Total shareholders' equity

69,609

65,764

Total liabilities and shareholders'

equity

112,959

117,565

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(millions

of dollars)

April 2,

2006

April 3,

2005

Operating Activities:

Net income

4,111

301

Adjustments to reconcile net income to net cash

provided by continuing operating activities:

Depreciation and amortization

1,351

1,366

Share-based compensation expense

172

22

Merger-related in-process research and development

charges

--

Intangible asset impairments and other associated

non-cash charges

--

1,213

Gains on disposal of investments, products and

product lines

(76)

(4)

Loss from discontinued operations

--

18

Gains on sales of discontinued operations

(5)

(65)

Deferred taxes from continuing operations

(714)

483

Other deferred taxes

--

(4)

Other non-cash adjustments

25

98

Changes in assets and liabilities (net of businesses

acquired and divested)

(903)

(237)

Net

cash provided by continuing operating activities

3,961

3,193

Investing

Activities:

Purchases of property, plant and equipment

(418)

(465)

Purchases of short-term investments

(2,735)

(4,891)

Proceeds from redemptions of short-term investments

10,438

2,531

Purchases of long-term investments

(216)

(494)

Proceeds from sales of long-term investments

437

Purchases of other assets

(35)

(70)

Proceeds from sales of other assets

Proceeds from the sales of businesses, product lines

and other products

93

Acquisitions, net of cash acquired

(1,440)

--

Other investing activities

(177)

149

Net

cash provided by/(used in) investing activities

5,431

(2,705)

Financing

Activities:

Increase in short-term borrowings, net

826

1,591

Principal payments on short-term borrowings

(8,056)

(205)

Proceeds from issuances of long-term debt

1,035

Principal payments on long-term debt

(1)

(1)

Purchases of common stock

(1,000)

(919)

Cash dividends paid

(1,743)

(1,400)

Stock option transactions and other

173

115

Net cash used in financing activities

(8,766)

(818)

Effect of exchange-rate changes on cash and cash

equivalents

(4)

(2)

Net increase/(decrease) in cash and cash equivalents

622

(332)

Cash and cash equivalents at beginning of period

2,247

1,808

Cash and cash equivalents at end of period

2,869

1,476

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

640

557

Interest

213

141

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation

We prepared the condensed consolidated financial statements

following the requirements of the Securities and Exchange Commission (SEC) for

interim reporting. As permitted under those rules, certain footnotes or other

financial information that are normally required by accounting principles

generally accepted in the United States of America (GAAP) can be condensed or

omitted. Balance sheet amounts and operating results for subsidiaries operating

outside the U.S. are as of and for the three-month periods ended

February 26, 2006 and February 27, 2005.

We made certain reclassifications to the 2005 condensed

consolidated financial statements to conform to the 2006 presentation.

Revenues, expenses, assets and liabilities can vary during

each quarter of the year. Therefore, the results and trends in these interim

financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements

included in this document. The financial statements include all normal and

recurring adjustments that are considered necessary for the fair presentation

of our financial position and operating results.

The information included in this Quarterly Report on

Form 10-Q should be read in conjunction with the consolidated financial

statements and accompanying notes included in Pfizer's Annual Report on

Form 10-K for the year ended December 31, 2005.

Note 2. Acquisitions and Dispositions

A. Acquisitions

On February 28, 2006, we completed the acquisition of the sanofi-aventis

world-wide rights, including patent rights and production technology, to

manufacture and sell Exubera, an inhaled form of insulin for use in adults with

type 1 and type 2 diabetes, and the insulin-production business and facilities

located in Frankfurt, Germany, previously jointly owned by Pfizer and sanofi-aventis,

for approximately $1.4 billion (including transaction costs). In

connection with the acquisition, as part of our preliminary purchase price

allocation, we recorded an intangible asset for developed technology rights of

approximately $1.0 billion, inventory valued at $218 million and

goodwill of approximately $166 million, all of which have been allocated

to our Human Health segment. The amortization of the developed technology

rights will be primarily included in Cost of Sales. Given the size and

complexity of the acquisition, the fair valuation and allocation work is still

being finalized and is expected to be substantially complete in the second

quarter. To the extent that our estimates need to be adjusted, we will do so.

Prior to the acquisition, in connection with our

collaboration agreement with sanofi-aventis, we recorded a research and

development milestone due to us from sanofi-aventis of approximately $118 million

($71 million, after tax) in Research and development expenses upon

the approval of Exubera in January 2006 by the Food and Drug Administration

(FDA).

B. Dispositions

We evaluate our businesses and product lines periodically

for strategic fit within our operations. As a result of our evaluation, we

decided to sell a number of businesses and product lines, certain of which

qualified for Discontinued operations treatment. As of December 31, 2005,

all of the transactions were completed. The impact of these divested businesses

and product lines was not material to the consolidated operating results of

Pfizer in the periods presented.

Assets held for sale

and Liabilities held for sale

on the balance sheet at April 2, 2006 and December 31, 2005, relate

primarily to assets in Europe that we intend to sell but that are not related

to Discontinued operations.

Note 3. Adoption of New Accounting Standards

On January 1, 2006, we adopted the provisions of Statement of

Financial Accounting Standards (SFAS) No. 123R, Share-Based Payment, as

supplemented by the interpretation provided by SEC Staff Accounting Bulletin

(SAB) No. 107, issued in March 2005. (SFAS 123R replaced SFAS 123, Stock-Based

Compensation, issued in 1995.) We have elected the modified prospective

application transition method of adoption and, as such, prior period financial

statements have not been restated. Under this method, the fair value of all stock

options granted or modified after adoption must be recognized in the consolidated

statement of income and total compensation cost related to nonvested awards not

yet recognized, determined under the original provisions of SFAS 123, must also

be recognized in the consolidated statement of income.

Prior to January 1, 2006, we accounted for stock options

under Accounting Principle Board Opinion (APB) No. 25, Accounting for Stock

Issued to Employees, an elective accounting policy permitted by SFAS 123.

Under this standard, since the exercise price of our stock options granted is

set equal to the market price on the date of the grant, we did not record any

expense to the condensed consolidated statement of income related to stock

options, unless certain original grant date terms were subsequently modified.

However, as required, we disclosed, in the Notes to Consolidated Financial

Statements, the pro forma expense impact of the stock option grants as if we

had applied the fair-value-based recognition provisions of SFAS 123.

The adoption of SFAS 123R primarily impacted our accounting

for stock options (See Note 13, Share-Based Payments).

Note 4. Asset Impairment Charge

In the first quarter of 2005, we recorded charges totaling

$1.2 billion ($766 million, net of tax) in connection with the

decision to suspend sales and marketing of Bextra. The pre-tax charge included

$1.1 billion related to the impairment of developed technology rights and

$10 million related to the write-off of machinery and equipment, both of which

were included in Other (income)/deductions - net (See Note 11, Goodwill

and Other Intangible Assets).

Note 5. Adapting to Scale Initiative

We incurred the following costs

in connection with our Adapting to Scale (AtS) productivity initiative, which

was launched in early 2005:

First

Quarter

(millions

of dollars)

2006

2005

Implementation

costs(a)

186

--

Restructuring

charges(b)

301

--

Total AtS costs

487

--

(a)

Included in Cost of sales

($124 million), Selling, informational and administrative expenses

($40 million), and Research and development expenses ($22 million).

(b)

Included

in Restructuring charges and merger-related costs.

Through April 2, 2006, the restructuring charges

primarily relate to our plant network optimization efforts and the

restructuring of our U.S. marketing and worldwide research and development operations,

while the implementation costs primarily relate to system and process

standardization, as well as the expansion of shared services.

The components of restructuring

charges associated with AtS follow:

(millions

of dollars)

Costs

Incurred

Through

April 2,

2006

Utilization

Through

April 2,

2006

Accrual

as of

April 2,

2006

(a)

Employee

termination costs

478

351

127

Asset

impairments

250

250

--

Other

23

16

751

608

143

(a)

Included

in Other current liabilities.

During the first quarter of 2006, we expensed $173 million

for Employee termination costs, $119 million for Asset

impairments and $9 million in Other. Through April 2, 2006,

Employee termination costs represent the approved reduction of

the workforce by 3,886 employees, mainly in manufacturing, sales and

research. We notified affected individuals and 3,610 employees were terminated

as of April 2, 2006. Employee termination costs are recorded as

incurred and include accrued severance benefits, pension and postretirement

benefits. Asset impairments primarily include charges to write-off inventory

and write down property, plant and equipment. Other primarily includes

costs to exit certain activities.

Note 6. Merger-Related Costs

We incurred the following

merger-related costs:

First

Quarter

(millions

of dollars)

2006

2005

Integration costs

106

Restructuring charges

113

Total

merger-related costs(a)

219

(a)

Included

in Restructuring charges and merger-related costs. Amounts in 2005

primarily relate to our acquisition of Pharmacia Corporation (Pharmacia),

which was completed on April 16, 2003.

Restructuring charges included severance, costs of vacating

duplicative facilities, contract termination and other exit costs.

Note 7. Taxes on Income

A. Taxes on Income

On January 23, 2006, the Internal Revenue Service (IRS)

issued final regulations on Statutory Mergers and Consolidations, which

impacted certain prior-period transactions. In the first quarter of 2006, we

recorded a tax benefit of $217 million, reflecting the total impact of these

regulations.

In the first quarter of 2005, we recorded an income tax

charge of $2.2 billion, included in Provision for taxes on income,

in connection with our decision to repatriate about $28.3 billion of

foreign earnings in accordance with the American Jobs Creation Act of 2004 (the

Jobs Act). This first quarter impact was based on preliminary information

available at the time. The final charge in 2005 was $1.7 billion on a

repatriation amount of $37 billion. The change in the repatriation and

corresponding tax amount was due primarily to guidance issued by the U.S.

Treasury in the second quarter of 2005, as well as our decision to increase the

amount of the repatriation.

B. Tax Contingencies

On January 25, 2006, the Company was notified by the IRS

Appeals Division that a resolution had been reached on the matter that we were

in the process of appealing related to the tax deductibility of a breakup fee

paid by Warner-Lambert Company in 2000. As a result, in the first quarter of

2006 we recorded a tax benefit of approximately $441 million related to

the resolution of this issue.

The IRS is currently conducting audits of the Pfizer Inc.

tax returns for the years 2002, 2003 and 2004. The 2005 and 2006 tax years are

also currently under audit under the IRS Compliance Assurance Process, a

recently introduced real time audit process.

With respect to Pharmacia Corporation, the IRS has completed

audits of the tax returns for the years 2000 through 2002 and is currently

conducting an audit for the 2003 tax year through the date of the merger with

Pfizer (April 16, 2003).

We periodically reassess the likelihood of assessments

resulting from audits of federal, state and foreign income tax filings. We

believe that our accruals for tax liabilities are adequate for all open years.

Note 8. Comprehensive Income/(Expense)

The components of comprehensive

income/(expense) follow:

First

Quarter

(millions

of dollars)

2006

2005

Net income

4,111

301

Other comprehensive

income/(expense):

Currency

translation adjustment and other

310

(277)

Net unrealized

gains/(losses) on derivative financial instruments

71

(19)

Net unrealized

gains/(losses) on available-for-sale securities

(71)

Minimum pension

liability

(12)

(2)

Total other

comprehensive income/(expense)

372

(369)

Total comprehensive

income/(expense)

4,483

(68)

Note 9. Financial Instruments

A. Long-Term Debt

On February

22, 2006, we issued the following Japanese yen fixed-rate bonds, to be used for

general corporate purposes:

$508 million

equivalent, senior unsecured notes, due February 2011, which pay interest

semi-annually, beginning on August 22, 2006, at a rate of 1.2%; and

$466 million

equivalent, senior unsecured notes, due February 2016, which pay interest

semi-annually, beginning on August 22, 2006, at a rate of 1.8%.

The notes were issued under a $5 billion

debt shelf registration filed with the SEC in November 2002. As of April 2,

2006, we had the ability to borrow $1 billion by issuing debt securities

under our existing debt shelf registration statement filed with the SEC in

November 2002.

B. Derivative

Financial Instruments and Hedging Activities

During the first quarter of

2006, we entered into the following incremental hedging activities:

Instrument(a)

Primary